Sandoz

Sandoz, a division of the Novartis group, works in the field of generic medicines and biosimilars. The company supplies a range of generic drugs to patients around the world.

As of 2023, the company employs 22,000 employees of more than 100 nationalities. The company's product portfolio at this time includes more than 1,500 drugs. Sandoz is headquartered in Basel, Switzerland.

History

2023

Separation from Novartis and going public

On October 4, 2023, the Swiss pharmaceutical company Novartis announced the separation of the Sandoz division, which specializes in the production of generic drugs and biosimilars, into an independent structure. Sandoz shares began trading on the Swiss Stock Exchange (SIX Swiss Exchange) under the ticker symbol SDZ.

According to Sandoz, generics and biosimilars account for about 80% of drugs sold globally, which is approximately 25% of the total cost of drugs. The industry continues to develop steadily, which opens up good prospects for business. As an independent company, Sandoz is expected to have more room to strengthen its market position.

Sandoz shares to trade on Swiss Stock Exchange

Today, a new era begins for Sandoz as a stand-alone structure, but our goal remains unchanged: to ensure access to cutting-edge drugs for patients. That's what we do best, have always done and will always do, "said Gilbert Ghostine, Sandoz's chairman.

Sandoz shares reportedly began trading at 24 Swiss francs (approximately $26.08 at the exchange rate as of October 4, 2023). Thus, the company is estimated at 10.3 billion Swiss francs (about $11.19 billion).

As part of the separation procedure, Novartis shareholders received one share of Sandoz for every five Novartis securities they owned. The spin-off of Sandoz is said to enable Novartis to complete the transformation and become one of the leading specialty pharmaceutical companies. In turn, Sandoz will have the opportunity to focus efforts on key areas of activity. We are talking, in particular, about 25 promising projects in the field of biological drugs.^[1]

Anna Bochkareva - General Director of Sandoz in Russia

The leadership of the Russian division of Sandoz (Sandoz JSC) has changed. Anna Bochkareva has been appointed General Director since October 1, 2023. In turn, Manlio Florenzano left the post of general director in connection with the end of the contract in Russia. Read more here.

2022

Total sales of $9.1 billion

In 2022, Sandoz's total sales amounted to $9.1 billion. US, and the main EBITDA indicator is $1.9 billion. UNITED STATES.

Purchase of respiratory device developer Coalesce Product Development

In March 2022, Sandoz announced the acquisition of respiratory device and drug delivery equipment developer Coalesce Product Development. Financial and other terms of the agreement are not disclosed. Read more here.

Recall due to cancer-causing substances

At the end of March 2022, Novartis-owned Sandoz is recalling 13 lots of long-release oral tablets of orphenadrine citrate 100mg after testing revealed unacceptable levels of a potential carcinogen called nitroso-orphenadrine. Read more here.

2015: 1,100 chemical compounds sold for $9.2 billion

Sandoz has a portfolio of medicines consisting of more than 1,100 chemical compounds, with sales of 9.2 billion dollars USA in 2015. At that time, the company is headquartered in Holzkirchen,. Germany Sandoz specializes in biosimilars and in the market of anti-infective, ophthalmic generic drugs, as well as generics used in transplantology.

1886: Establishing a Company

The history of the company began in 1886. It includes the creation of the drug Calcium Sandoz in 1929, the world's first oral penicillin in 1951 and the world's first biosimilar in 2006.

Notes